Race for AI-developed drugs heats up: Wegovy-maker Novo Nordisk ties up with OpenAI after rival Eli Lilly seals deal
In a significant development within the pharmaceutical industry, Danish drugmaker Novo Nordisk has announced a collaboration with OpenAI, the parent company of ChatGPT. This partnership aims to leverage artificial intelligence (AI) to accelerate the discovery and development of new treatment options for patients, particularly those suffering from obesity and diabetes.
The Collaboration with OpenAI
On April 14, 2026, Novo Nordisk revealed that its partnership with OpenAI would enhance its ability to analyze complex datasets, identify promising new drugs, and reduce the time required for a medicine to progress from the research phase to patient use. According to reports from CNBC, the collaboration is expected to include pilot programs across various sectors, including research and development, manufacturing, and commercial operations, with full integration anticipated by the end of 2026.
Statements from Leadership
Novo Nordisk’s CEO, Mike Doustdar, emphasized the importance of this partnership, stating, “There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives.” He further noted that integrating AI into daily operations would allow the company to analyze datasets at an unprecedented scale, identify unseen patterns, and test hypotheses more rapidly than ever before.
OpenAI’s CEO, Sam Altman, echoed this sentiment, asserting, “AI is reshaping industries, and in life sciences, it can help people live better, longer lives.” This collaboration reflects a growing trend among drug manufacturers to harness AI’s potential to improve operational efficiency and innovation in drug development.
The Role of AI in Drug Development
As the pharmaceutical industry increasingly turns to AI, experts suggest that while the technology holds great promise for discovering new treatments, the industry has yet to fully realize its capabilities. Currently, AI is primarily applied at specific stages of drug development rather than as a comprehensive end-to-end solution.
In the near term, AI could provide more practical benefits by streamlining the traditionally lengthy processes associated with clinical trials, such as identifying suitable patients and trial sites. Despite the potential, many clinical trials still rely on conventional methods, indicating that there is significant room for improvement in how AI is utilized within the industry.
Partnerships to Enhance Drug Discovery
Novo Nordisk’s collaboration with OpenAI is part of a broader strategy to enhance its AI initiatives. The company has also partnered with Nvidia to utilize Gefion’s sovereign AI supercomputer, aimed at accelerating drug discovery through innovative AI applications. This partnership is expected to lead to the development of customized AI models and agents that Novo Nordisk can use for early research and clinical development.
Competition in the Weight-Loss Market
The race for AI-developed drugs is intensifying, particularly in the lucrative weight-loss market. Novo Nordisk is competing closely with its U.S. rival, Eli Lilly, which has recently made significant strides in this area. Novo Nordisk’s Wegovy pill, launched in January, is part of its strategy to regain market share in the obesity treatment sector.
In March 2026, Eli Lilly secured a $2.75 billion deal with Insilico Medicine to introduce AI-developed drugs to the global market. This agreement includes an upfront payment of $115 million, with additional payments contingent on regulatory approvals and commercial milestones, as well as royalties on future sales. This move underscores the competitive landscape as both companies vie for leadership in the rapidly evolving pharmaceutical market.
Conclusion
The collaboration between Novo Nordisk and OpenAI marks a pivotal moment in the race for AI-driven drug development. As both companies explore the potential of AI to transform the pharmaceutical industry, the implications for patient care and treatment options could be profound. With the ongoing advancements in technology and the increasing integration of AI in drug discovery, the future of healthcare may witness significant changes that enhance the quality of life for millions of patients worldwide.
Note: This article is based on information available as of April 2026 and aims to provide insights into the current trends in the pharmaceutical industry regarding AI collaboration and drug development.
